Sartorius $90m IntelliCyt acquisition adds cell analysis capabilities

By Dan Stanton contact

- Last updated on GMT

Image: iStock/pichet_w
Image: iStock/pichet_w

Related tags: Contract research organization

Sartorius has expanded its bio-analytics capabilities through the $90m (€81m) acquisition of IntelliCyt.

The deal sees Germany’s Sartorius bolster its lab products and services division, adding Albuquerque, New Mexico instrumentation, software and reagent firm IntelliCyt.

“Sartorius is already present in [the bio-analytics] market with its broad lab portfolio for sample preparation,”​ Sartorius spokesperson Petra Kirchhoff told “This is a further step that will especially enhance our presence with scientists who work in the pharmaceutical and biotech industries as well as academia.”

The deal includes IntelliCyt’s I Que Screener platform which is based on cytometry, according to Kirchhoff, integrates instruments, software and reagents to enable rapid, high-throughput cell analysis for assessing multiple cellular parameters.

“The I Que Screener also minimises sample size requirements, while making it possible to deliver content-rich results in just minutes. As sample preparation is simple, it is also possible to trace cell reactions right from the very beginning.”

M&A strategy

Sartorius has traditionally been a bioprocessing equipment and solutions firm, and about 74% of its revenues still come from this division, which focuses on single-use products for the manufacture of biopharmaceuticals.

But the firm is also pursuing a diversification programme to help grow the business, which has seen such acquisitions in its Lab Products & Services Division as the contract research organisation (CRO) BioOutsource, which it bought last year​ adding biopharma testing services including safety monitoring, drug characterisation and comparability testing of biologics and vaccines.

“We are following our Total Solution Provider Strategy for Biopharma already since more than a decade, and have recently addressed the earlier steps of the value chain,”​ said Kirchhoff, “so process development and the addition of IntelliCyt connects us with our clients even earlier in drug discovery.”

She added: “Complementary additions are possible in both our divisions, Bioprocess Solutions as well as Lab Products &Services.”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more